Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nucana Plc ADR (NCNA)

Nucana Plc ADR (NCNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,251
  • Shares Outstanding, K 2,643
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,370 K
  • EBIT $ -42 M
  • EBITDA $ -42 M
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -3.49
  • Number of Estimates 3
  • High Estimate -2.74
  • Low Estimate -3.88
  • Prior Year -4.00
  • Growth Rate Est. (year over year) +12.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2250 +2.86%
on 11/22/24
1.8300 -31.15%
on 10/28/24
-0.5300 (-29.61%)
since 10/25/24
3-Month
1.2250 +2.86%
on 11/22/24
8.2500 -84.73%
on 09/16/24
-5.8300 (-82.23%)
since 08/23/24
52-Week
1.2250 +2.86%
on 11/22/24
19.4100 -93.51%
on 03/13/24
-10.9250 (-89.66%)
since 11/24/23

Most Recent Stories

More News
NuCana plc Reports Encouraging Clinical Data for NUC-7738 and NUC-3373, Highlights Financial Position and Future Milestones

NuCana reported encouraging results for NUC-7738 and NUC-3373 in recent clinical trials, with financial updates and a projected cash runway.Quiver AI SummaryNuCana plc announced encouraging Phase 2 results...

NCNA : 1.2600 (+2.44%)
German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022,...

NCNA : 1.2600 (+2.44%)
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates...

NCNA : 1.2600 (+2.44%)
NuCana Announces Receipt of NASDAQ Notice

EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification...

NCNA : 1.2600 (+2.44%)
NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other...

NCNA : 1.2600 (+2.44%)
NuCana to Participate in the 2022 Jefferies Healthcare Conference

EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host...

NCNA : 1.2600 (+2.44%)
NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study...

NCNA : 1.2600 (+2.44%)
NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-FU ...

NCNA : 1.2600 (+2.44%)
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373...

NCNA : 1.2600 (+2.44%)
NuCana to Participate in Two Upcoming Investor Conferences

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and...

NCNA : 1.2600 (+2.44%)

Business Summary

NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in...

See More

Key Turning Points

3rd Resistance Point 1.3400
2nd Resistance Point 1.3200
1st Resistance Point 1.2900
Last Price 1.2600
1st Support Level 1.2400
2nd Support Level 1.2200
3rd Support Level 1.1900

See More

52-Week High 19.4100
Fibonacci 61.8% 12.4633
Fibonacci 50% 10.3175
Fibonacci 38.2% 8.1717
Last Price 1.2600
52-Week Low 1.2250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar